For semaglutide, while the core patent (protecting the molecule itself) expires in 2026, Novo Nordisk has likely filed secondary patents on aspects like formulations, dosage regimens, or delivery mechanismspotentially extending protection into the 2030s
Clinical Trial Registry (2025) 12
As scientific interest continues to grow, peptides remain an important area of investigation in advanced biomedical and regenerative medicine research
Schleicher et al, 2016), the detrimental effect of eosinophils in L
Others notice gradual improvement over the next 2472 hours
En funcin de la evidencia farmacolgica, de los datos de investigaciones clnicas y de estudios de vida real, los AR-GLP1 pueden considerarse como agentes nefroprotectores para los pacientes con DM2 y ERC, caracterizada por su elevada morbilidad secundaria al compromiso renal y CV.